Tumor immune escape mechanisms: impact of the neuroendocrine system

被引:56
作者
Lang, K [1 ]
Entschladen, F [1 ]
Weidt, C [1 ]
Zaenker, KS [1 ]
机构
[1] Univ Witten Herdecke, Inst Immunol, D-58448 Witten, Germany
关键词
tumor cell escape mechanisms; neurotransmitters; neoneurogenesis; metastasis;
D O I
10.1007/s00262-006-0126-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Tumor cells act upon, and react to both their proximate and more distant environment, the mechanisms by which this is achieved being both autocrine and paracrine in nature. This interaction, however, takes place not only between adjacent malignant cells, but also non-malignant cells such as those of the immune system, the latter also partaking in the modeling of the tumor environment. Although tumor cells descend from normal tissue cells and thus bear in classical immunological terms 'self signals', it is evident that the immune system is able to recognize tumor cells as a harassment for the body and in consequence tries to eliminate these cells. On the counterpart, tumor cells acquire various characteristics which allow them to evade this immunological surveillance, and have been collectively coined with the term "tumor escape mechanisms". This review will describe and summarize current understanding of tumor escape strategies, and also more closely elaborate on the modulatory role of the neuroendocrine system in the immune system-tumor cell interaction.
引用
收藏
页码:749 / 760
页数:12
相关论文
共 152 条
[1]
Tumor-derived exosomes:: a new source of tumor rejection antigens [J].
André, F ;
Scharz, NEC ;
Chaput, N ;
Flament, C ;
Raposo, G ;
Amigorena, S ;
Angevin, E ;
Zitvogel, L .
VACCINE, 2002, 20 :A28-A31
[2]
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles [J].
Andreola, G ;
Rivoltini, L ;
Castelli, C ;
Huber, V ;
Perego, P ;
Deho, P ;
Squarcina, P ;
Accornero, P ;
Lozupone, F ;
Lugini, L ;
Stringaro, A ;
Molinari, A ;
Arancia, G ;
Gentile, M ;
Parmiani, G ;
Fais, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (10) :1303-1316
[3]
Do CD4+CD25+ immunoregulatory T cells hinder tumor immunotherapy? [J].
Antony, PA ;
Restifo, NP .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (03) :202-206
[4]
Inhibition of the alloantibody response by CD95 ligand [J].
Arai, H ;
Chan, SY ;
Bishop, DK ;
Nabel, GJ .
NATURE MEDICINE, 1997, 3 (08) :843-848
[5]
Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[6]
Bennett MW, 1998, J IMMUNOL, V160, P5669
[7]
Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis [J].
Bergquist, J ;
Josefsson, E ;
Tarkowski, A ;
Ekman, R ;
Ewing, A .
ELECTROPHORESIS, 1997, 18 (10) :1760-1766
[8]
LOSS OF HLA CLASS-I EXPRESSION IN PROSTATE-CANCER - IMPLICATIONS FOR IMMUNOTHERAPY [J].
BLADES, RA ;
KEATING, PJ ;
MCWILLIAM, LJ ;
GEORGE, NJR ;
STERN, PL .
UROLOGY, 1995, 46 (05) :681-686
[9]
Mechanisms of loss of HLA class I expression on colorectal tumor cells [J].
Browning, M ;
Petronzelli, F ;
Bicknell, D ;
Krausa, P ;
Rowan, A ;
Tonks, S ;
Murray, N ;
Bodmer, J ;
Bodmer, W .
TISSUE ANTIGENS, 1996, 47 (05) :364-371
[10]
BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1